Meng, Xiangjiao

ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation

Yang, Y., Wu, M., Cao, D., Yang, C., Jin, J., Wu, L., Hong, X., Li, W., Lu, L., Li, J., et al. (2021) · Science Advances

Cell death mechanisms and regulationinterferon and immune responses

Cited by 187

A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial

Ma, Y., Yang, Y., Huang, Y., Fang, W., Xue, J., Meng, X., Fan, Y., Fu, S., Wu, L., Zheng, Y., et al. (2025) · Nature Medicine

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 122

Immune Microenvironment Differences Between Squamous and Non-squamous Non–small-cell Lung Cancer and Their Influence on the Prognosis

Meng, X., Gao, Y., Yang, L., Jing, H., Teng, F., Huang, Z., & Xing, L. (2019) · Clinical Lung Cancer

Cancer Immunotherapy and BiomarkersLung Cancer Research Studies

Cited by 66

Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Fang, W., Li, X., Wang, Q., Meng, X., Zheng, W., Sun, L., Yao, W., Zhuang, W., Fan, Y., Zhuo, M., et al. (2025) · BMJ

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 51

Results of a phase 1/2 study of MHB036C: A potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced or metastatic solid tumors.

Lu, S., Zhang, Q., Meng, X., Sun, Y., Xiong, H. H., Lv, D., Wang, X., Wu, L., Dong, X., Ji, Y., et al. (2024) · Journal of Clinical Oncology

Cancer therapeutics and mechanismsMonoclonal and Polyclonal Antibodies Research

Cited by 1